172 related articles for article (PubMed ID: 23179902)
1. Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.
Liu W; Ren HY; Dong YJ; Wang LH; Yin Y; Li Y; Qiu ZX; Cen XN; Shi YJ
Int J Hematol; 2012 Dec; 96(6):764-72. PubMed ID: 23179902
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
Blanco B; Pérez-Simón JA; Sánchez-Abarca LI; Carvajal-Vergara X; Mateos J; Vidriales B; López-Holgado N; Maiso P; Alberca M; Villarón E; Schenkein D; Pandiella A; San Miguel J
Blood; 2006 May; 107(9):3575-83. PubMed ID: 16282346
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
4. CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation.
Giegold O; Ogrissek N; Richter C; Schröder M; Herrero San Juan M; Pfeilschifter JM; Radeke HH
J Immunol; 2013 Apr; 190(7):3696-705. PubMed ID: 23447686
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C
Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1β induces CXCR3-mediated chemotaxis to promote umbilical cord mesenchymal stem cell transendothelial migration.
Guo YC; Chiu YH; Chen CP; Wang HS
Stem Cell Res Ther; 2018 Oct; 9(1):281. PubMed ID: 30359318
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.
Nencioni A; Schwarzenberg K; Brauer KM; Schmidt SM; Ballestrero A; Grünebach F; Brossart P
Blood; 2006 Jul; 108(2):551-8. PubMed ID: 16537813
[TBL] [Abstract][Full Text] [Related]
11. A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.
He S; Cao Q; Qiu Y; Mi J; Zhang JZ; Jin M; Ge H; Emerson SG; Zhang Y; Zhang Y
J Immunol; 2008 Dec; 181(11):7581-92. PubMed ID: 19017947
[TBL] [Abstract][Full Text] [Related]
12. SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation.
Kim CH; Broxmeyer HE
J Leukoc Biol; 1999 Sep; 66(3):455-61. PubMed ID: 10496316
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
Pai CC; Hsiao HH; Sun K; Chen M; Hagino T; Tellez J; Mall C; Blazar BR; Monjazeb A; Abedi M; Murphy WJ
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1899-904. PubMed ID: 25064746
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Al-Homsi AS; Feng Y; Duffner U; Al Malki MM; Goodyke A; Cole K; Muilenburg M; Abdel-Mageed A
Exp Hematol; 2016 Sep; 44(9):771-777. PubMed ID: 27224851
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
van der Heijden JW; Oerlemans R; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Clin Exp Rheumatol; 2009; 27(1):92-8. PubMed ID: 19327235
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
Sun K; Li M; Sayers TJ; Welniak LA; Murphy WJ
Blood; 2008 Aug; 112(4):1522-9. PubMed ID: 18539902
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
